These dual antibody-conjugated nanoreactors demonstrate potential for checkpoint blockade immunotherapy (CBIT) by effectively targeting and blocking PD-L1 and CD24 proteins present on breast cancer cells, specifically TNBC cells. The gene discussed is CD24; the disease is breast cancer.